|Articles|October 1, 2018

Is the Price Right Figure 2

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Trump Administration Pauses Search for New Head of CDC: Report

ByNicholas Jacobus

March 26th 2026

FDA Approves Avlayah for Treatment of Hunter Syndrome

ByNicholas Jacobus

March 26th 2026

How Have Recent Regulatory Actions Impacted the Rare Disease Space?

ByMike Hollan,Laksheeta Johari

March 25th 2026

Rebates tied to volume thresholds, market share agreements, or performance metrics may be realized months later—yet ASP must be reported quarterly. Credit: Stock.Adobe.com/Aria Armoko.

Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right

ByThani Jambulingam, PhD

March 24th 2026

FDA Approves Expanded Indication for Imcivree as Treatment for Hypothalamic Obesity

ByNicholas Jacobus

March 23rd 2026

Is the Price Right Figure 2

Newsletter

Related Content

Trump Administration Pauses Search for New Head of CDC: Report

FDA Approves Avlayah for Treatment of Hunter Syndrome

How Have Recent Regulatory Actions Impacted the Rare Disease Space?

Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right

FDA Approves Expanded Indication for Imcivree as Treatment for Hypothalamic Obesity

Trending on PharmExec

Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock

Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science

FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement

How Have Recent Regulatory Actions Impacted the Rare Disease Space?